Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?
You may also be interested in...
Big Pharma Embraces Microbiome Research; Partnering Poised To Follow
Microbiome-based research is gaining credibility as a means to discover novel therapeutics. Now big pharmas like J&J and Pfizer are evaluating partnering opportunities in the burgeoning field – with potential therapies starting to enter the clinic – as they look to strike the appropriate balance between internal and external research.
Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan
Biogen will purchase GSK spinout Convergence to bolster its pain portfolio, while Tekmira and OnCore are merging to create a new company focused on hepatitis B. Two J&J units struck deals during the week in Alzheimer’s and gastrointestinal indications, as Lilly teamed up with Merck and Bristol for combo trials to keep its drugs relevant in the PD-1 world.
Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.